5 Einträge gefunden

1. Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine

   1. Laakmann, Elena
   2. Emons, Julius
   3. Taran, Florin-Andrei
   4. Janni, Wolfgang
   5. Uhrig, Sabrina
   6. Overkamp, Friedrich
   7. Kolberg, Hans-Christian

   2020 - Forschungsinformationssystem des UKE
2. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

   1. Huebner, Hanna
   2. Kurbacher, Christian M
   3. Kuesters, Geoffrey
   4. Hartkopf, Andreas D
   5. Lux, Michael P
   6. Huober, Jens
   7. Volz, Bernhard

   2020 - Forschungsinformationssystem des UKE
3. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany

   1. Schneeweiss, Andreas
   2. Ettl, Johannes
   3. Lüftner, Diana
   4. Beckmann, Matthias W
   5. Belleville, Erik
   6. Fasching, Peter A
   7. Fehm, Tanja N

   2020 - Forschungsinformationssystem des UKE
4. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab

   1. Michel, Laura L
   2. Hartkopf, Andreas D
   3. Fasching, Peter A
   4. Kolberg, Hans-Christian
   5. Hadji, Peyman
   6. Tesch, Hans
   7. Häberle, Lothar

   2020 - Forschungsinformationssystem des UKE
5. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial

   1. de Gregorio, Amelie
   2. Häberle, Lothar
   3. Fasching, Peter A
   4. Müller, Volkmar
   5. Schrader, Iris
   6. Lorenz, Ralf
   7. Forstbauer, Helmut

   2020 - Forschungsinformationssystem des UKE